Compare Invesco Ltd. (IVZ) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Tempus AI — how do they compare? Invesco Ltd. trades at $29.68 (market cap $13.15B), while Tempus AI trades at $49.09 (market cap $8.69B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.9% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| IVZ | TEM | |
|---|---|---|
Market Cap | $13.15B | $8.69B |
Sector | Financials | Broad Market / Factor |
52-Week High | $30.30 | $103.25 |
52-Week Low | $20.20 | $42.37 |
Enterprise Value | $23.39B | $9.37B |
Dividend Yield | 2.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $29.57, down 0.2% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company reported revenue growth to $6.38B in 2025 but posted a net loss of -$281.70M, reflecting margin pressures. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Positive cash flow from operations of $1.53B in 2025 highlights operational strength, while analyst sentiment leans neutral with a consensus price target of $30.64.
The stock presents a cautious opportunity with solid revenue growth and improving cash flows offset by profitability challenges. Near-term catalysts include potential earnings recovery and dividend payments, but risks from competitive pressures and macroeconomic volatility warrant careful monitoring. The current price near the consensus target suggests limited upside without fundamental improvements.
Tempus AI (TEM) trades at $48.41, down 7.74% in the last 24 hours, reflecting a bearish technical signal. The company reported revenue of $1.27 billion in 2025 but a net loss of $245.03 million, with negative profitability metrics. Recent news highlights growth in AI-driven diagnostics and data services, including FDA approvals and research collaborations. The stock is trading well below the analyst consensus price target of $68.50, with a majority of analysts maintaining a Buy rating.
The outlook for TEM is a mix of high growth potential in healthcare AI and significant financial risk due to persistent losses. Investment opportunity lies in its proprietary data platform and expanding market reach, but risks include execution challenges and cash burn. Wall Street sentiment remains positive on long-term prospects, but investors should weigh the volatility against the company's unproven path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
